MedTrace Logo

Intramuscular Ketorolac at Two Single-Dose Regimens

NCT04763876 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2025-10-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to evaluate a single 15 mg intramuscular (IM) dose of ketorolac for analgesic non-inferiority versus a single 60 mg IM dose for the treatment of acute MSK pain in a military emergency department (ED) that services Department of Defense (DoD), Department of Veteran Affairs (VA), and foreign military beneficiaries

Conditions

Interventions

DRUG

Ketorolac Injection 15 mg

A single dose of 15 mg ketorolac administered intramuscularly.

DRUG

Ketorolac Injection 60 mg

A single dose of 60 mg ketorolac administered intramuscularly.

Sponsors & Collaborators

  • William Beaumont Army Medical Center

    lead FED

Principal Investigators

  • Nathaniel J Turner, MPAS · Department of Emergency Medicine, William Beaumont Army Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-27
Primary Completion
2020-11-09
Completion
2021-02-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04763876 on ClinicalTrials.gov